Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

Recommendations

  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

    IFLR1000
  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

    • 06/11/2018
    • Articles

    Establishment of Observatory for Pharmaceutical Industry in Belgium

    Life Sciences | Today’s Belgian Official Journal (Belgisch Staatsblad/Moniteur belge) has published the Royal Decree of 25 May 2018 establishing an observatory for the pharmaceutical industry (Koninklijk Besluit van 25 mei 2018 houdende oprichting van een Observatorium voor de farmaceutische industrie/Arrêté royal du 25 mai 2018 portant création d'un Observatoire du secteur pharmaceutique).

    Read more
    • 06/11/2018
    • Articles

    European Union Intellectual Property Office Report on IPR Infringement 2018

    Life Sciences | On 7 June 2018, the European Union Intellectual Property Office (“EUIPO”) published a “Synthesis Report” on intellectual property right (“IPR”) infringement (the “Report”). Based on research since 2013, the Report details the contribution of intellectual property to the EU economy and the cost of counterfeiting and piracy to international trade. It also outlines actions being undertaken by national, regional and international bodies to combat IPR infringements, and specifically counterfeiting and piracy activities.

    Read more
    • 06/11/2018
    • Articles

    UK Competition Appeal Tribunal Annuls In Part Excessive Medicine Price Decision of Competition and Markets Authority Against Pfizer and Flynn Pharma

    Life Sciences | On 7 June 2018, the UK Competition Appeal Tribunal (“CAT”) annulled in part a decision of the UK Competition and Markets Authority (“CMA”) of 7 December 2016 which had fined Pfizer and medicines distributor Flynn Pharma on account of excessive pricing for phenytoin sodium capsules which are indicated for the treatment of epilepsy.

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.